Who makes salbutamol UDV?

salbutamol UDV is developed by Boehringer Ingelheim.

What development phase is salbutamol UDV in?

salbutamol UDV is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

salbutamol UDV

Boehringer Ingelheim · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	salbutamol UDV
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma (PHASE3)
A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) (PHASE4)
Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

salbutamol UDV CI brief — competitive landscape report
salbutamol UDV updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI